Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARX517 + Pasritamig |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARX517 | ARX 517|ARX-517|JNJ-95298177|JNJ95298177|JNJ95298177 | PSMA Antibody 22 | ARX517 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against PSMA linked to pAF-AS269, which targets the anti-microtubule agent to PSMA-expressing cells, potentially inhibiting growth of PSMA-positive tumor cells (PMID: 39172730). | |
| Pasritamig | JNJ78278343|JNJ 78278343|JNJ-78278343 | CD3 Antibody 119 | Pasritamig (JNJ-78278343) is an IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T-lymphocytes, which may lead to T-lymphocyte activation and killing of tumor cells expressing KLK2 (PMID: 40450573). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07082920 | Phase I | ARX517 + Pasritamig | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Recruiting | USA | 0 |